SLBT vs FTH
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
SLBT · SL Science$0.94 ▲ 4.16%
FTH · Faeth Therapeutics$22.05 ▲ 10.69%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- SLBT -91.0%
- FTH +129.4%
Head to head
| Metric | SLBT | FTH |
|---|---|---|
| Price | $0.94 | $22.05 |
| Change today | ▲ 4.16% | ▲ 10.69% |
| Market cap | $525.71M | $569.86M |
| Return, 3 months | -66.9% | -22.8% |
| Return, year to date | -91.1% | +106.7% |
| Return, 1 year | -91.0% | +142.3% |
| P/E (TTM) | -85.2 | -1.0 |
| P/B | 78.1 | 3.5 |
| P/E percentile vs own 5y | 97th | 96th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -34.7% | – |
| Net profit growth (YoY) | -220.6% | -224.3% |
| Gross margin | 38.4% | – |
| Operating margin | -178.8% | – |
| Net margin | -178.4% | – |
| Return on equity | -74.9% | -195.3% |
| Analyst target vs. price | – | +161.2% |
| Analyst buy share | – | 100% |
| RSI (14) | 26 | 50 |
| 30-day volatility | 111.8% | 96.9% |
| Max drawdown, 1 year | -93.0% | -69.2% |
| Trend read | Strong downtrend | Leaning bullish |
| Analyst consensus | – | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- FTH is the largest of the group by market value.
- FTH has returned the most over the past year.
- SLBT carries the lowest trailing P/E.
- FTH has been the calmest stock over the last 30 days.